For acute coronary syndrome (heart attack or unstable angina), patients usually undergo dual antiplatelet therapy for about one year, which prevents blood clots but increases the risk of bleeding, which can lead to negative consequences. This study examined the association between internal bleeding after ACS and subsequent cancer diagnoses.
The records of 3644 inpatients with acute coronary syndrome who were prescribed dual antiplatelet therapy at the hospital were analyzed. Alvaro Cunqueiro Hospital in Vigo, Spain. Experts followed patients for bleeding and malignancy for an average of 56.2 months. The relationship between bleeding and the absolute risk of cancer diagnosis was examined.
During the study, 1,215 patients were diagnosed with bleeding, and 227 had new malignancies. Experts found that bleeding increased the risk of a new diagnosis of cancer threefold. On average, 4.6 months passed between the onset of bleeding and the diagnosis of cancer. Moreover, the relationship between bleeding and the development of malignant neoplasms remained regardless of whether the patient underwent dual antiplatelet therapy or not.